Sulfamazone

{{Short description|Chemical compound}}

{{more citations needed|date=April 2022}}

{{Drugbox

| verifiedrevid = 443486461

| IUPAC_name = (1,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)-{[4-[(6- methoxypyridazin-3-l)sulfamoyl]phenyl]amino} methanesulfonic acid

| image = Sulfamazone.svg

| alt = Skeletal formula of sulfamazone

| width = 300

| image2 = Sulfamazone-3D-spacefill.png

| alt2 = Space-filling model of the sulfamazone molecule

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number = 65761-24-2

| ATC_prefix = J01

| ATC_suffix = ED09

| PubChem = 187764

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| ChEBI = 131721

| ChEMBL = 2104921

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = D7B8U8VA9J

| KEGG_Ref = {{keggcite|correct|kegg}}

| KEGG = D07241

| ChemSpiderID = 163211

| smiles = CC1=C(C(=O)N(N1C)C2=CC=CC=C2)C(NC3=CC=C(C=C3)S(=O)(=O)NC4=NN=C(C=C4)OC)S(=O)(=O)O

| StdInChI = 1S/C23H24N6O7S2/c1-15-21(23(30)29(28(15)2)17-7-5-4-6-8-17)22(38(33,34)35)24-16-9-11-18(12-10-16)37(31,32)27-19-13-14-20(36-3)26-25-19/h4-14,22,24H,1-3H3,(H,25,27)(H,33,34,35)

| StdInChIKey = BGLHAKAJGYLSOX-UHFFFAOYSA-N

| C=23 | H=24 | N=6 | O=7 | S=2

}}

Sulfamazone (INN) is a sulfonamide antibiotic with antipyretic properties.{{cite journal | vauthors = Zhao Z, Dai X, Li C, Wang X, Tian J, Feng Y, Xie J, Ma C, Nie Z, Fan P, Qian M, He X, Wu S, Zhang Y, Zheng X | display-authors = 6 | title = Pyrazolone structural motif in medicinal chemistry: Retrospect and prospect | journal = European Journal of Medicinal Chemistry | volume = 186 | pages = 111893 | date = January 2020 | pmid = 31761383 | pmc = 7115706 | doi = 10.1016/j.ejmech.2019.111893 }}